110 related articles for article (PubMed ID: 35471260)
1. Quebec Health-related Quality of Life Population Norms in Adults Using the SF-6Dv2: Decomposition by Sociodemographic Data and Health Problems.
Poder TG; Carrier N
Med Care; 2022 Jul; 60(7):545-554. PubMed ID: 35471260
[TBL] [Abstract][Full Text] [Related]
2. Cancer population norms using a new value set for the SF-6Dv2 based on the preferences of patients with breast or colorectal cancer in Quebec.
Touré M; Sfairy SM; Bédard SK; McFadden N; Hanel R; Lemay F; He J; Pavic M; Poder TG
Qual Life Res; 2024 Jun; 33(6):1605-1619. PubMed ID: 38642218
[TBL] [Abstract][Full Text] [Related]
3. Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2.
Poder TG; Fauteux V; He J; Brazier JE
Value Health; 2019 Jul; 22(7):837-842. PubMed ID: 31277832
[TBL] [Abstract][Full Text] [Related]
4. Quebec Health-Related Quality-of-Life Population Norms Using the EQ-5D-5L: Decomposition by Sociodemographic Data and Health Problems.
Poder TG; Carrier N; Kouakou CRC
Value Health; 2020 Feb; 23(2):251-259. PubMed ID: 32113631
[TBL] [Abstract][Full Text] [Related]
5. EQ-5D-5L and SF-6Dv2 utility scores in people living with chronic low back pain: a survey from Quebec.
Poder TG; Wang L; Carrier N
BMJ Open; 2020 Sep; 10(9):e035722. PubMed ID: 32933957
[TBL] [Abstract][Full Text] [Related]
6. Psychometric properties of the SF-6Dv2 in an Iranian breast cancer population.
Nahvijou A; Safari H; Ameri H
Breast Cancer; 2021 Jul; 28(4):937-943. PubMed ID: 33666840
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the measurement properties of SF-6Dv2 and EQ-5D-5L in a Chinese population health survey.
Xie S; Wang D; Wu J; Liu C; Jiang W
Health Qual Life Outcomes; 2022 Jun; 20(1):96. PubMed ID: 35710429
[TBL] [Abstract][Full Text] [Related]
8. Population Norms for SF-6Dv2 and EQ-5D-5L in China.
Xie S; Wu J; Xie F
Appl Health Econ Health Policy; 2022 Jul; 20(4):573-585. PubMed ID: 35132573
[TBL] [Abstract][Full Text] [Related]
9. Differences in health utilities between cancer patients and the general population: The case of Quebec using the SF-6Dv2.
Touré M; Poder TG
Soc Sci Med; 2024 Jun; 351():117001. PubMed ID: 38805836
[TBL] [Abstract][Full Text] [Related]
10. SF-6D population norms for the Hong Kong Chinese general population.
Wong CKH; Mulhern B; Cheng GHL; Lam CLK
Qual Life Res; 2018 Sep; 27(9):2349-2359. PubMed ID: 29797176
[TBL] [Abstract][Full Text] [Related]
11. Predicting SF-6Dv2 utility scores for chronic low back pain using the Oswestry Disability Index and Roland-Morris Disability Questionnaire.
Poder TG; Carrier N
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):105-110. PubMed ID: 32275183
[No Abstract] [Full Text] [Related]
12. Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2.
Brazier JE; Mulhern BJ; Bjorner JB; Gandek B; Rowen D; Alonso J; Vilagut G; Ware JE;
Med Care; 2020 Jun; 58(6):557-565. PubMed ID: 32412942
[TBL] [Abstract][Full Text] [Related]
13. Valuing SF-6Dv2 in Australia Using an International Protocol.
Mulhern B; Norman R; Brazier J
Pharmacoeconomics; 2021 Oct; 39(10):1151-1162. PubMed ID: 34250578
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the EQ-5D 3L and the SF-6D (SF-36) contemporaneous utility scores in patients with chronic kidney disease in Sri Lanka: a cross-sectional survey.
Kularatna S; Senanayake S; Gunawardena N; Graves N
BMJ Open; 2019 Feb; 9(2):e024854. PubMed ID: 30772857
[TBL] [Abstract][Full Text] [Related]
15. Estimating the monetary value of a Quality-Adjusted Life-Year in Quebec.
Kouakou CRC; He J; Poder TG
Eur J Health Econ; 2024 Jul; 25(5):787-811. PubMed ID: 37656261
[TBL] [Abstract][Full Text] [Related]
16. Valuing the SF-6Dv2 in the capital of Iran using a discrete choice experiment with duration.
Daroudi R; Zeraati H; Poder TG; Norman R; Olyaeemanesh A; Sari AA; Ameri H
Qual Life Res; 2024 Jul; 33(7):1853-1863. PubMed ID: 38630166
[TBL] [Abstract][Full Text] [Related]
17. Chilean population norms derived from the health-related quality of Life SF-6D.
Garcia-Gordillo MA; Collado-Mateo D; Olivares PR; Adsuar JC
Eur J Health Econ; 2018 Jun; 19(5):675-686. PubMed ID: 28631248
[TBL] [Abstract][Full Text] [Related]
18. SF-6Dv2 preference value set for health utility in food allergy.
Dufresne É; Poder TG; Samaan K; Lacombe-Barrios J; Paradis L; Des Roches A; Bégin P
Allergy; 2021 Jan; 76(1):326-338. PubMed ID: 32533705
[TBL] [Abstract][Full Text] [Related]
19. Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration.
Mulhern BJ; Bansback N; Norman R; Brazier J;
Med Care; 2020 Jun; 58(6):566-573. PubMed ID: 32221100
[TBL] [Abstract][Full Text] [Related]
20. The Simplified Chinese version of SF-6Dv2: translation, cross-cultural adaptation and preliminary psychometric testing.
Wu J; Xie S; He X; Chen G; Brazier JE
Qual Life Res; 2020 May; 29(5):1385-1391. PubMed ID: 31950328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
